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Aspirin impairs acetyl-coenzyme A 
metabolism in redox-compromised 
yeast cells
Gianluca Farrugia1,2, Maria Azzopardi1,2, Christian saliba1, Godfrey Grech3, Angelina S. Gross  4,  
Jelena pistolic5, Vladimir Benes  5, Neville Vassallo2, Joseph Borg  6, Frank Madeo4,7, 
tobias eisenberg  4,7,8 & Rena Balzan1,2
Aspirin is a widely used anti-inflammatory and antithrombotic drug also known in recent years for its 
promising chemopreventive antineoplastic properties, thought to be mediated in part by its ability 
to induce apoptotic cell death. However, the full range of mechanisms underlying aspirin’s cancer-
preventive properties is still elusive. In this study, we observed that aspirin impaired both the synthesis 
and transport of acetyl-coenzyme A (acetyl-CoA) into the mitochondria of manganese superoxide 
dismutase (MnSOD)-deficient Saccharomyces cerevisiae EG110 yeast cells, but not of the wild-type 
cells, grown aerobically in ethanol medium. This occurred at both the gene level, as indicated by 
microarray and qRT-PCR analyses, and at the protein level as indicated by enzyme assays. These results 
show that in redox-compromised MnSOD-deficient yeast cells, but not in wild-type cells, aspirin starves 
the mitochondria of acetyl-CoA and likely causes energy failure linked to mitochondrial damage, 
resulting in cell death. Since acetyl-CoA is one of the least-studied targets of aspirin in terms of the 
latter’s propensity to prevent cancer, this work may provide further mechanistic insight into aspirin’s 
chemopreventive behavior with respect to early stage cancer cells, which tend to have downregulated 
MnSOD and are also redox-compromised.
Aspirin (acetylsalicylic acid, ASA) is a widely used anti-inflammatory, cardioprotective and antithrombotic 
drug that has, in recent years, been found to have promising chemopreventive, antineoplastic properties1–3. 
These are attributed not only to aspirin’s anti-inflammatory and anti-platelet effects, but also to its propensity to 
induce programmed cell death, such as apoptosis, in cancer cells2,4,5. The full range of mechanisms underlying 
aspirin-induced apoptosis of malignant cells is still not fully understood, and has aroused considerable research 
efforts involving the use of several eukaryotic experimental models. One such model is the yeast Saccharomyces 
cerevisiae, long used to study apoptosis in living organisms since it retains several core eukaryotic cellular pro-
cesses, including the hallmark features of apoptosis6–9. In particular, yeast serves as a valuable tool to study 
mitochondria-associated regulated cell death10–12.
Since mitochondrial manganese superoxide dismutase (MnSOD) deficiency can reprogram cells to a cancer 
prone form of metabolism (Warburg effect)13, we decided to use the redox-compromised, MnSOD-deficient S. 
cerevisiae EG110 cells as a model of cancer cells. In fact, cancer cells tend to manifest downregulated MnSOD 
during the early stages of their development14–16 and are also redox-compromised17.
In our previous studies, aspirin reproducibly and robustly induced an apoptotic phenotype in 
MnSOD-deficient S. cerevisiae cells, but not in wild-type yeast cells, during aerobic growth in ethanol 
medium18–21. We also showed that the aspirin-induced apoptosis in redox-compromised MnSOD-deficient yeast 
cells is associated with severe mitochondrial dysfunction, including events such as overproduction of mito-
chondrial superoxide radicals (O2˙−), oxidation of mitochondrial NAD(P)H21, decreased respiration, release of 
cytochrome c and disruption of the mitochondrial membrane potential20. Overall, these results indicated that the 
mitochondrial milieu constitutes a critical cellular target of aspirin.
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In this study, we examined the effect of aspirin on the expression of genes involved in acetyl-coenzyme A 
(acetyl-CoA) generation and its transport into the mitochondria of MnSOD-deficient yeast cells growing aer-
obically on ethanol medium. Although acetyl-CoA is a metabolite of fundamental importance in eukaryotic 
organisms, since it drives the tricarboxylic acid (TCA) cycle required for energy generation, it remains one of the 
most poorly studied potential targets of aspirin in the context of the latter’s antineoplastic effects2. Hence, this 
work provides novel mechanistic insight into the metabolic changes associated with aspirin-mediated apoptosis. 
This may be of relevance to aspirin’s chemopreventive behavior in redox-compromised cancer cells during their 
early stages of development.
Methods
Yeast strains and plasmids. The yeast strains used in this study include the wild-type Saccharomyces cere-
visiae EG103 (MATα leu2-3 112 his3Δ1 trp1-289a ura3-52 GAL+) and the MnSOD-deficient yeast strain EG110 
(EG103 sod2 Δ:: TRP1), kindly provided by Edith Gralla, University of California, Los Angeles and Valeria C. 
Culotta, Johns Hopkins University, Baltimore.
ADH2-overexpression in yeast. To generate ADH2-overexpressing strains (EG103 pGPD-ADH2 
and EG110 pGPD-ADH2) the constitutive glyceraldehyde-3-phosphate dehydrogenase promoter 
(pGPD) was introduced to the endogenous ADH2 locus according to the method described by Janke 
et al.22. The plasmid pYM-N15 served as the template to generate a linear PCR fragment with primers 
5′-ACAAAAAGCATACAATCAACTATCAACTATTAACTATATCGTAATACACAATGCGTACGCT 
GCAGGTCGAC-3′(ADH2_S1) and 5′-TTGCCGTTGGATTCGTAGAAGATAATGGCTTTTTGAGTTT 
CTGGAATAGACATCGATGAATTCTCTGTCG-3′(ADH2_S4 primer). Strains carrying an HA-tagged version 
of Adh2 were generated by similar approaches using pYM-N16 (EG103 pGPD-3HA-ADH2 and EG110 pGPD-
3HA-ADH2) or pYM-N14 (EG103 ADH2-6HA and EG110 ADH2-6HA) as templates and primers ADH2_S1 and 
ADH2_S4 or 5′-GGCATACTTGATAATGAAAACTATAAATCGTAAAGACATAAGAGATCCGCTTAATCGA 
TGAATTCGAGCTCG-3′ (ADH2_S2) and 5′-AGATGGAGAAGGGCCAAATTGCTGGTAGATACGTTGTTGA 
CACTTCTAAACGTACGCTGCAGGTCGAC-3′(ADH2_S3), respectively. Correct integration of linear DNA 
fragments was verified by colony PCR using primers 5′-CCTGTGTAACTGATTAATCCTGC-3′ (ADH2_up) 
and 5′-GTCGACCTGCAGCGTACG-3′ (S1/S3_reverse) for all N-terminal integrations and primers 5′-GGAAGAA 
TTGTTTACCTCGCTC-3′ (ADH2 -fw) and S1/S3_reverse for C-terminal tagging.
Culture conditions. Yeast cells were aerobically cultivated in YPE medium (1% (w/v) yeast extract, 2% (w/v) 
bactopeptone and 3% (v/v) ethanol) in the absence and presence of 15 mM aspirin (acetylsalicylic acid, ASA) 
(Sigma-Aldrich), at 28 °C with constant shaking at 250 rpm. The pH of the aspirin-treated YPE medium was 
adjusted to 5.5 using 1 M Trizma base (Sigma-Aldrich), prior to inoculation. For plates, cells were cultivated on 
YPD medium (1% (w/v) yeast extract, 2% (w/v) bactopeptone and 2% (w/v) glucose) containing 2% (w/v) agar, 
at a sustained incubation temperature of 28 °C.
Measurement of cell growth and viability. Cell growth was measured as the optical density at 600 nm 
(OD600). Cell viability was measured by plating serial dilutions of yeast cell cultures onto YPD plates (500 cells 
per plate). The plates were left to incubate for at least 48 h at 28 °C after which colony forming units (cfus) were 
counted. The cfu counts of aspirin-treated cells were then presented as fold changes in viability by normalizing 
them to the cfu counts of untreated cells.
RNA preparation for microarrays. Yeast cells were aerobically cultivated for 48 h (mid-log phase) in YPE 
medium in both the absence and presence of 15 mM ASA, at a temperature of 28 °C with constant shaking at 
250 rpm. Harvested yeast cells were mechanically lysed by beadmilling, using a micro-minibeadbeater (Biospec), 
in the presence of acid-washed glass beads (500 nm diameter) and lysis buffer (RLT) provided by the Qiagen 
RNeasy Mini Kit. Three cycles of 60 s beadmilling followed by 60 s of cooling on ice were carried out. Total yeast 
RNA was extracted and purified using the Qiagen RNeasy Mini Kit, according to the manufacturer’s instructions. 
The quantity and quality of total RNA was determined using a Thermo Scientific Nanodrop spectrophotometer 
and an Agilent Bioanalyzer. Moreover, the RNA samples were subjected to reverse transcription polymerase chain 
reaction (RT-PCR) in order to verify that they were suitable for complementary DNA (cDNA) synthesis and not 
significantly contaminated by guanidine salts or ethanol, which interfere with the downstream microarray hybrid-
ization. One microgram of the RNA was used to synthesize cDNA using a Quantitect Reverse Transcription Kit 
(Qiagen). The cDNA was probed for the constitutive, intron-spanning YRA1 gene using the custom-designed 
primers 5′-TGTCGGTGGTACTCGTGGTA-3′ (YRA1-F) and 5′-TAGTCCGCCATTTCCTTGTC-3′ (YRA1-R), 
at an annealing temperature of 54 °C, together with the Thermo Scientific 2X ReddyMix PCR Master Mix. The 
RT-PCR products were then visualized by electrophoresis on a 2% (v/v) agarose gel under UV light.
Microarray hybridization and data analysis. Preparation of complimentary RNA and subsequent 
hybridization to whole yeast genome microarrays were carried out using the GeneChip Yeast Genome 2.0 Array 
(Affymetrix). Normalization of the resulting microarray data was carried out using the robust multi-array average 
(RMA) method23, implemented with AltAnalyze Version 2.0.8.1 (University of Cincinnati).
Normalized log2-expression values, fold changes, moderated t-statistics and corresponding P-values were 
determined for the probe sets of every individual S. cerevisiae gene present on the microarray chip. Differentially 
expressed genes with Benjamini-Hochberg-adjusted P-values < 0.05 and fold changes ≥1.5 (in presence of ASA 
versus absence of ASA) were identified. Microarray hybridization and analysis were carried out on three biolog-
ical replicates.
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The normalized microarray data sets were used for principle components analysis (PCA) to identify correla-
tions and outliers among individual aspirin-treated and untreated samples. The normalized datasets were further 
analyzed by hierarchical cluster analysis. Both PCA and hierarchical clustering were carried out using the online 
ClustVis web tool24.
Gene Ontology (GO) Analysis. Identification of enriched biological process, molecular function and cel-
lular component GO categories was carried out by over-representation analysis (ORA) using GO-Elite software 
Version 1.2.6, which is integrated with AltAnalyze. Statistical significance of GO enrichment was determined 
using the Fisher Exact Test with a threshold P-value < 0.05.
All microarray datasets related to this study were deposited in the GEO (NCBI) repository and are accessible 
through the Accession number: GSE115660.
Microarray result validation by quantitative polymerase chain reaction (qRT-PCR). The respec-
tive messenger RNA (mRNA) levels of differentially expressed S. cerevisiae target genes were determined by 
qRT-PCR to validate the microarray results. The extraction of total RNA from yeast cells, verification of its qual-
ity and the subsequent preparation of cDNA were carried out as described in a previous section. Each sample 
of resulting cDNA was probed in triplicate for target genes using the custom-designed oligonucleotide primer 
pairs (Integrated DNA Technologies) shown in Supplementary Table S1a. This was carried out by using the 2X 
Quantitect SYBR-Green PCR Master Mix (Qiagen) and Rotor Gene Q Thermocycler (Qiagen), according to the 
manufacturer’s instructions. Target gene expression in the samples was normalized against the geometric average 
expression of GLC7 and SMD2 reference genes as an internal control (Supplementary Table S1b). These reference 
genes exhibit constitutive expression which does not change significantly across the different experimental condi-
tions of this study, including the absence and presence of ASA (Supplementary Table S2). The calculation, based 
on the ∆∆Ct method, of normalized relative quantities (NRQs) of target genes as a measure of their differential 
expression in yeast cells grown in the absence and presence of aspirin, was carried out using qbase + (Biogazelle). 
Differentially expressed genes with significant P-values < 0.05 and fold changes >1.5 (in presence of ASA versus 
absence of ASA) were identified. The qRT-PCR assays were carried out on three biological replicates.
Enzyme activity measurements. Yeast total cell extracts, cultivated for 48 h in ethanol medium in the 
absence and presence of aspirin, were prepared by beadmilling, using a micro-minibeadbeater (Biospec), in the 
presence of acid-washed glass beads (500 nm diameter). Alcohol dehydrogenase (ADH) activity was measured 
according to Vallee and Hoche25, acetyl-coenzyme A synthetase (ACS) activity was measured according to van 
den Berg et al.26 and carnitine acetyl transferase (CAT) enzyme activity was quantified according to Chase27. 
Peroxisomal citrate synthase activity was measured according to Srere28 in yeast cytosolic fractions previously 
isolated from the mitochondria according to Glick and Pon29. The protein concentrations of total and cytosolic 
yeast cell extracts were determined with the Pierce Bicinchoninic Acid Assay Kit (Pierce), using bovine serum 
albumin (BSA) as a protein standard.
Immunoblotting. Immunoblotting after sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) of the cytosolic fractions to confirm the absence of any mitochondrial protein, was carried out using 
standard protocols, with antibodies specific for yeast cytosolic glucose-6-phosphate dehydrogenase (anti-G6PD, 
Sigma-Aldrich, A9521, 1:7500) and mitochondrial heat shock protein 60 (anti-Hsp60, Abcam, ab59458, 1:1000).
Immunoblotting after SDS-PAGE of chemically lysed yeast30 was performed using standard protocols with 
antibodies specific for yeast glyceraldehyde-3-phosphate dehydrogenase (anti-GAPDH, ThermoFisher, MA5-
15738, 1:10.000) and HA (Sigma, H9658, 1:10000).
Statistical analyses. Pairwise comparisons between treatments and controls were examined using the 
unpaired, two-tailed t-test (GraphPad Prism, Version 6.0). Multiple comparisons between treatments and con-
trols were analyzed by one-way ANOVA with the post-hoc Bonferroni test. Where appropriate, the nonparamet-
ric Mann-Whitney U-test and Kruskal-Wallis test were applied to confirm the results of the t-tests and one-way 
ANOVA tests, respectively. Significance was accepted at a P-value < 0.05.
Results
Aspirin induces differential expression of genes involved in mitochondrial acetyl-CoA metabo-
lism and transport. The mechanism of aspirin-induced mitochondrial deterioration is not fully understood. 
To further characterize changes upon aspirin insults, we performed a transcriptome analysis of MnSOD-deficient 
(EG110) and MnSOD-proficient (EG103) yeast cells grown in ethanol medium. Principle Components Analysis 
(PCA) (Fig. 1a) of the normalized EG110 and EG103 microarray datasets indicated tight clustering and distinct 
separation of redox-compromised EG110 biological replicates from wild-type EG103 biological replicates, with 
87.8% of the variance mainly explained by principle component 1 (PC1). Likewise, distinct clustering of aspi-
rin-treated versus untreated EG110 sample groups was observed along principal component 2 (PC2), with a 
variance of 4.8%. This distinct clustering of aspirin-treated versus untreated EG110 sample groups was corrobo-
rated by the hierarchical clustering heatmaps (Fig. 1b), showing that aspirin clearly induced a strong and uniform 
transcriptional change in mRNA expression of MnSOD-deficient EG110 replicates.
The normalized, wild-type EG103 yeast microarray datasets also indicated distinct clustering and separation 
of aspirin-treated versus untreated biological replicates, along PC2 (Fig. 1a), corroborated by the accompanying 
heatmaps shown in Fig. 1b, which demonstrate that aspirin likewise altered mRNA transcription in EG103 yeast 
cells, but to a much lesser extent than in EG110 cells. In fact, follow-up application of Gene Ontology (GO) anal-
ysis for MnSOD-deficient EG110 cells (Fig. 2) and EG103 cells (Fig. 3) suggests that aspirin had a relatively much 
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lower effect on the wild-type EG103 cells in comparison to their redox-compromised EG110 counterparts, given 
that relatively few GO categories were enriched by aspirin in the wild-type strain (Fig. 3).
On the other hand, GO-analysis results obtained in MnSOD-deficient EG110 cells, additionally showed that 
aspirin significantly downregulated genes associated with at least 19 GO categories, the most strongly and sig-
nificantly enriched being the ‘cellular ketone metabolic process’ (GO:0042180) ontology (Fig. 2), a category that 
did not appear enriched by aspirin in wild-type EG103 cells (Fig. 3). Aspirin-induced apoptosis involves mito-
chondria and mitochondrial metabolism-dependent processes18,20,21,31,32. In light of this, we selected a number of 
significantly downregulated genes associated with the enriched GO:0042180 category and involved in mitochon-
drial metabolism and metabolite transport (ADH2, ACS1, CAT2, YAT2, CRC1, CIT2, SFC1 and AGP2 - Fig. 2 and 
Table 1), to further study their role in aspirin-induced cell death. The microarrays indicated that these selected 
genes were significantly downregulated by aspirin in redox-compromised MnSOD-deficient EG110 cells, but 
not in wild-type EG103 cells, after 48 h of growth in ethanol medium (see Table 1). Acetyl-CoA is a metabolite of 
Figure 1. Principal components analysis (PCA) and heatmaps of normalized expression data obtained from 
redox-compromised EG110 yeast cells and wild-type EG103 yeast cells grown in ethanol medium in the absence 
and presence of aspirin. (a) Principle Component Analysis (PCA) two dimensional scatter plot of normalized 
expression data obtained from aspirin-treated (green and red dots) and untreated (control – purple and blue 
dots) samples of redox-compromised, MnSOD-deficient EG110 and wild-type EG103 yeast cells, respectively, 
cultivated for 48 h in ethanol medium. Three biological replicates of each were considered. Axis X = PC1: 
PCA Component 1 (87.8% variance) separating EG110 from EG103 yeast cells; Y = PC2: PCA Component 
2 (4.8% variance) separating aspirin-treated cells from untreated cells. (b) Heatmap depicting differential 
gene expression due to aspirin in individual replicate samples of EG110 and EG103 yeast cells, as compared 
to untreated EG110 and EG103 yeast cells after 48 h of cultivation in ethanol medium. The heat map shows all 
genes that were significantly changed by aspirin in EG110 cells. The expression of these same genes was also 
followed in the wild-type EG103 cells, in the absence and presence of aspirin. Columns represent biological 
replicates, whereas rows represent genes. Gene expression levels are shown using a pseudocolour scale (−2.0 to 
2.0) with red denoting high expression levels and blue denoting low expression levels.
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Figure 2. Gene Ontology (GO) analysis of differentially expressed mRNA transcripts in aspirin (ASA)-treated 
MnSOD-deficient EG110 yeast cells. All statistically significant GO terms of downregulated (a) and upregulated 
(b) mRNA transcripts (>1.5-fold) in ASA-treated EG110 are shown, each belonging to one of the following GO 
categories: biological processes (blue bars), cellular components (yellow bars) or molecular function (red bars). 
The calculated -log10 (P-value) values reflect the statistical significance of each GO term enrichment. The genes 
selected for further study, which include ACS1, ADH2, CIT2, CAT2, YAT2 and AGP2 are associated with the 
enriched cellular ketone metabolic process ontology.
Figure 3. Gene Ontology (GO) analysis of differentially expressed mRNA transcripts in aspirin (ASA)-treated 
wild-type EG103 yeast cells. All statistically significant GO terms of downregulated (a) and upregulated (b) 
mRNA transcripts in ASA-treated EG103 cells are shown, each belonging to one of the following GO categories: 
biological processes (blue bars), cellular components (yellow bars) or molecular function (red bars). The 
calculated −log10 (P-value) values reflect the statistical significance of each GO term enrichment.
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central importance in eukaryotic organisms such as respiring yeast, since it drives the TCA cycle in mitochondria 
to facilitate energy generation.
Amongst the genes most significantly downregulated by aspirin in EG110 yeast cells, is the ACS1 gene encod-
ing one of 2 isoforms of acetyl-CoA synthetases (Acs1) (2.72-fold downregulation, P < 0.001; Table 1). Acs1 is 
an important source of acetyl-CoA which relies on the upstream acetaldehyde-derived supply of acetate during 
yeast cell growth in ethanol medium26,33,34. Under these growth conditions, acetaldehyde is itself derived from the 
oxidation of ethanol, catalyzed by the Adh2 isoform of alcohol dehydrogenase, encoded by the gene ADH235,36, 
which was also markedly downregulated by aspirin in EG110 (3.01-fold downregulation, P < 0.001), but not in 
EG103 (MnSOD-proficient wild-type) yeast cells (Table 1).
During growth in non-fermentable media such as ethanol, acetyl-CoA molecules formed by peroxisomal 
and cytosolic acetyl-CoA synthetases must be converted into acetyl unit derivatives and shuttled into the mito-
chondria via the glyoxylate cycle and/or the carnitine shuttle37,38 in order to drive the TCA cycle. The microarray 
results indicated that the genes CIT2 and SFC1, encoding essential glyoxylate cycle pathway proteins38–40, and the 
genes CAT2, YAT2 and CRC1, which encode critical carnitine shuttle proteins41–43, were significantly downregu-
lated in aspirin-treated EG110 (>1.5-fold downregulation, P < 0.001), but not in EG103, yeast cells (Table 1). This 
was also the case for AGP2, a gene encoding a yeast cell plasma membrane carnitine transporter protein, which 
facilitates cellular import of carnitine from the surrounding growth medium44.
The aspirin-induced differential expression of the aforementioned genes, as indicated by the microarrays, was 
validated by qRT-PCR analysis (Fig. 4) using primers listed in Supplementary Table S1.
Altogether, the microarray and qRT-PCR results strongly suggest that in MnSOD-deficient EG110 
yeast cells grown in ethanol medium, aspirin significantly reduces transcription of several acetyl-CoA 
metabolism-associated genes, potentially disrupting the pathways involved in cytosolic acetyl-CoA synthesis and 
its transport into the mitochondria.
Aspirin reduces the activities of key enzymes involved in acetyl-CoA synthesis and mito-
chondrial transport. Induced alterations in the expression profile of gene transcripts do not necessarily 
correlate with expression of their respective encoded proteins45. Moreover, post-translational modifications of 
encoded gene products are not taken into account by microarrays and qRT-PCR techniques. Hence, to verify the 
aspirin-induced impairment of acetyl-CoA metabolic pathways in EG110 yeast cells, as indicated by the microar-
ray (Table 1) and qRT-PCR results (Fig. 4), the activities of enzymes encoded by the genes ACS1, CAT2, YAT2, 
CIT2 and ADH2 were measured in protein extracts of MnSOD-deficient EG110 and wild-type EG103 yeast cells 
grown for 48 h in ethanol medium, in the presence and absence of aspirin. These enzymes were selected for fur-
ther investigation, using UV-visible spectrophotometric enzyme activity assays, on the basis of their importance 
in mediating acetyl-CoA synthesis and transport into the mitochondria.
In agreement with the microarray and qRT-PCR results, aspirin significantly decreased the overall acetyl-CoA 
synthetase enzyme activity in EG110, but not in EG103, yeast cells grown for 48 h in ethanol medium (Table 2). 
There are two known acetyl-CoA synthetase isoforms present in yeast cells - Acs1 and Acs2 (encoded respectively 
by ACS1 and ACS2)26,46. Both of these isoforms actively ligate acetate to CoA to yield acetyl-CoA, however, the 
expression of Acs1 is known to be heavily de-repressed in the absence of glucose and in cases where there is a 
prevalence of non-fermentable carbon sources, such as ethanol and acetate26,47. Moreover, the affinity of Acs1 for 
acetate is reported to be several times greater than that of the constitutively expressed Acs2 isoform, suggesting 
that Acs1 is primarily responsible for acetyl-CoA synthesis during growth on non-fermentable carbon sources 
Affymetrix 
Probe Set
Ensembl 
ID
Gene 
Name Encoded Protein
Fold Change
EG110 + ASA 
vs EG110
EG103 + ASA 
vs EG103
EG110 vs 
EG103#
1774070_at YMR303C ADH2 Ethanol-induced alcohol dehydrogenase isoform 2 −3.01*** −1.06NS 1.40**
1772915_at YAL054C ACS1 Acetyl-CoA synthetase isoform 1 (repressed by glucose) −2.72*** 1.01
NS 1.08NS
1774377_at YML042W CAT2 Carnitine acetyltransferase (peroxisomal and mitochondrial) −2.56*** 1.04
NS −1.72***
1771757_at YER024W YAT2 Carnitine acetyltransferase (cytosolic) −2.68*** 1.05NS −2.69***
1774778_at YOR100C CRC1 Mitochondrial inner membrane carnitine transporter −4.52*** 1.04
NS −1.62***
1773515_at YCR005C CIT2 Peroxisomal citrate synthase −1.72*** 1.01NS −1.23*
1774072_at YJR095W SFC1 Mitochondrial succinate-fumarate transporter −1.60*** −1.05NS −1.01NS
1773859_at YBR132C AGP2 Plasma membrane carnitine transporter −1.91*** −1.01NS −1.80***
Table 1. Aspirin (ASA)-induced differential expression of genes involved in acetyl-CoA synthesis and transport 
into the mitochondria of Saccharomyces cerevisiae EG110 and EG103 yeast cells grown in ethanol medium. 
EG103 is the wild-type strain, whilst EG110 is the MnSOD-deficient yeast strain. Cells were cultivated in rich 
medium containing the non-fermentable carbon source ethanol (YPE) in the absence and presence of 15 mM 
aspirin (previously added to the medium with adjustment of the pH to 5.5 with 1 M Trizma base) for 48 h at 
28 °C, 250 rpm. Microarray analysis of total yeast RNA to assess aspirin-induced differential gene expression 
was carried out using the GeneChip Yeast Genome 2.0 Array (Affymetrix), as described in Methods. The minus 
sign (−) indicates downregulation. ***(P < 0.001); **(P < 0.01); *(P < 0.05); NS, (P ≥ 0.05); aspirin treatment 
vs no treatment, #untreated EG110 vs untreated EG103, unpaired two-tailed t-test.
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such as ethanol26. This implies that the aspirin-induced decrease of acetyl-CoA synthetase activity observed in 
redox-compromised EG110 yeast cells, largely reflects an impairment of Acs1 activity. This does not necessarily 
exclude an accompanying aspirin-induced impairment of Acs2 activity. However, the aspirin-induced decline in 
ACS2 gene expression was less than 1.5-fold, as opposed to the 2.72-fold downregulation of ACS1.
Similarly, aspirin decreased the overall carnitine acetyltransferase (CAT) enzyme activity in 
redox-compromised EG110, but not in wild-type EG103, yeast cells (Table 2). Yeast CAT enzymes include Cat2 
present in both the mitochondria and peroxisomes, together with Yat2 present in the cytosol. These enzymes 
participate in the transport of acetyl-CoA-derived acetyl groups (in the form of acetylcarnitine) from the perox-
isomes and cytosol to the mitochondria, reconverting them to acetyl-CoA upon entry into the mitochondria, to 
drive the TCA cycle38,43,48. Hence, the reduced activity of CAT enzymes observed in aspirin-treated EG110 yeast 
cells indicates an aspirin-induced impairment of the carnitine shuttle pathway in these cells during growth in 
ethanol medium, as initially suggested by the microarray and qRT-PCR results.
Likewise, the activity of peroxisomal citrate synthase (Cit2) declined significantly in MnSOD-deficient EG110 
yeast cells, but remained unaltered in wild-type EG103 yeast cells cultivated for 48 h in aspirin-treated ethanol 
medium (Table 2). The activity of Cit2 was measured in cytosolic extracts that were free of mitochondrial protein, 
as verified by immunoscreening (Supplementary Fig. S1). This was important since yeast mitochondria contain 
the citrate synthases Cit1 and Cit349,50, which would have interfered with the activity assay readings of peroxiso-
mal Cit2 present in the cytosolic extracts.
The observed decrease of peroxisomal Cit2 activity in aspirin-treated EG110 yeast cells (Table 2) indicates that 
the glyoxylate cycle, which facilitates transport of acetyl-CoA-derived succinate (a TCA cycle intermediate) to the 
mitochondria38 is possibly impaired by aspirin much like the carnitine shuttle pathway.
Aspirin also caused a considerable decrease in Adh2 activity in MnSOD-deficient, redox-compromised EG110 
yeast cells after 48 h of aerobic growth in ethanol medium, but not in wild-type EG103 cells (Table 2). This result 
corroborates the significant aspirin-induced downregulation of ADH2 expression in EG110, but not in EG103, 
yeast cells observed in the microarray and qRT-PCR results.
Increasing ADH2 expression has no effect on growth and survival of aspirin-treated MnSOD-deficient 
yeast cells. In view of the pronounced aspirin-induced suppression of ADH2 expression (3.01-fold down-
regulation, P < 0.001; Table 1) and Adh2 enzyme activity in MnSOD-deficient EG110 yeast cells (42% decreased 
Figure 4. Aspirin-induced log2 fold change expression of target genes in wild-type (EG103) and MnSOD-
deficient (EG110) Saccharomyces cerevisiae yeast cells grown in the absence and presence of aspirin (ASA). 
The figure shows aspirin-induced log2 fold change expression of the target genes ADH2, ACS1, CAT2, YAT2, 
CRC1, CIT2, SFC1, and AGP2 in EG103 yeast cells (grey bars) and EG110 yeast cells (white bars), after 48 h of 
aerobic growth in YPE medium treated with 15 mM aspirin. Total RNA isolated from cultured yeast cells was 
analyzed by qRT-PCR using gene-specific primers (see Supplementary Table S1). In all cases, the expression 
of target genes was normalized against GLC7 and SMD2 reference genes using the comparative ∆∆Ct method 
in qbase + (Biogazelle). Results are the mean ± standard error of the mean (SEM), from three independent 
biological replicates. NS, not significant (P > 0.05); **, moderately significant (P < 0.01); ***, highly significant 
(P < 0.001); unpaired two-tailed t-test. ADH2 – Alcohol Dehydrogenase 2, ACS1 - Acetyl-CoA Synthetase 1; 
CIT2 – CITrate synthase 2; SFC1 – Succinate-Fumarate Carrier 1; CAT2, YAT2 – Carnitine AcetylTransferases, 
CRC1 – Carnitine Carrier 1, AGP2 – high-Affinity Glutamine Permease 2, GLC7 – GlyCogen 7, SMD2 - Core 
Sm protein Sm D2.
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activity, P < 0.01; Table 2), and taking into account the important upstream role of Adh2 in yeast acetyl-CoA 
synthesis during growth on ethanol medium35,51,52, we attempted to rescue the redox-compromised EG110 cells 
by increasing the expression of ADH2 (and consequently of active Adh2). The ADH2-overexpressing strains 
EG110 pGPD-ADH2, and the respective wild-type EG103 pGPD-ADH2 control, were constructed by replacing 
the endogenous promoter of ADH2 with the constitutive GPD promoter.
Immunoblot analysis of strains carrying HA fusion constructs of the Adh2 protein allowed us to compare the 
quantity of expressed Adh2 after growth of the cells in ethanol medium, in the absence and presence of aspirin. 
This assay indicated an aspirin-induced decrease of Adh2 expression in MnSOD-deficient EG110 cells (Fig. 5). 
However, the immunoblots also showed that the amount of expressed Adh2 was greater in strains containing the 
GPD promoter.
We next compared Adh2 activity of the Adh2-overexpressing strain to that of EG110 after 48 h of growth in 
aspirin-treated ethanol medium. As a result of the overexpression, EG110 pGPD-ADH2 cells sustained a constant 
level of Adh2 activity even in the presence of aspirin, whereas the EG110 cells did not (Fig. 6a).
However, the sustained Adh2 enzyme activity did not confer any significant benefit, in terms of growth and 
survival, to EG110 pGPD-ADH2 cells, either in the absence or presence of aspirin (Fig. 6b,c). EG110 pGPD-ADH2 
cells failed to show improved viability compared to EG110 yeast cells after treatment with aspirin (Fig. 6c).
Thus, restoring Adh2 activity alone was insufficient to prevent aspirin-induced toxicity in redox-compromised 
MnSOD-deficient yeast cells, even though Adh2-mediated ethanol oxidation into acetaldehyde lies upstream of 
acetyl-CoA synthesis36.
Discussion
The principal scope of this investigation was to further understand the mechanisms underlying aspirin-induced 
apoptosis, which takes place in redox-compromised MnSOD-deficient S. cerevisiae EG110 yeast cells, but not in 
wild-type EG103 yeast cells, after cultivation in ethanol medium18. With this aim in mind, we first carried out 
microarray studies to investigate potential aspirin-induced differential gene expression in EG110 and EG103 
yeast cells, after 48 h of cultivation (early to mid-log phase). The distinct response to aspirin of these two strains, 
described in past studies carried out in our laboratory18–20, was indeed again made immediately apparent in our 
transcriptome analysis, which showed that aspirin altered the gene expression profile of EG110 cells to a greater 
and significantly different extent than that of EG103 cells (Figs 1–3). This is particularly true for genes involved in 
acetyl-CoA synthesis and transport (Table 1).
The dissimilarity in the magnitude of aspirin’s effect on EG110 versus EG103 gene expression profiles can 
be readily explained by the deficiency of the mitochondrial antioxidant enzyme MnSOD in mutant EG110 (but 
not in wild-type EG103) cells that imparts very distinct gene expression profiles to these two strains (Fig. 1). In 
fact, GO analysis revealed several enriched pathways in aspirin-untreated EG110 cells with respect to EG103 
yeast cells (Supplementary Fig. S4). Interestingly, overall altered expression of genes due to genotypic differences 
between the two strains accounted for the greatest variance between all analyzed conditions (Fig. 1a). One can 
speculate that some of these genotype-induced transcriptional adaptations are involved in unfolding the sen-
sitivity to aspirin in MnSOD-deficient EG110 cells. For instance, genes involved in acetyl-CoA synthesis and 
transport were altered due to the genotype differences, irrespective of aspirin treatment. Several of these genes 
were already reduced due to the genotype and thus, aspirin further aggravated their down-regulation (Table 1).
The microarray results presented in Table 1 and validated by qRT-PCR (Fig. 4) notably indicated that, in 
EG110 cells grown in ethanol medium, aspirin significantly downregulated the expression of genes involved in 
central energy metabolism, particularly in pathways of acetyl-CoA synthesis and metabolite transport to the 
mitochondria. Subsequent enzyme activity assays confirmed that aspirin markedly impaired the activity of a 
Strainsa
Specific enzyme activity (units mg−1 of total protein)
EG110 EG103
Control +ASA Control +ASA
Alcohol dehydrogenasec 6.14 +/− 0.781 3.56 +/− 0.356** 14.72 +/− 1.869 13.99 +/− 1.016NS
Acetyl-CoA synthetased 0.32 +/− 0.031 0.20 +/− 0.021** 0.46 +/− 0.017 0.53 +/− 0.047NS
Carnitine acetyltransferasee 0.20 +/− 0.005 0.14 +/− 0.005** 0.29 +/− 0.020 0.28 +/− 0.026NS
Peroxisomal citrate synthasef 0.37 +/− 0.044 0.17 +/− 0.038* 0.38 +/− 0.128 0.30 +/− 0.099NS
Table 2. Enzyme activities in Saccharomyces cerevisiae cells grown for 48 h in ethanol medium in the absence 
and presence of aspirin (ASA)b. aEG103 is the wild-type strain, whilst EG110 is the MnSOD-deficient yeast 
strain. bCells were cultivated in rich medium containing the non-fermentable carbon source ethanol (YPE). 
Fifteen millimolar aspirin was added to the medium and the pH adjusted to 5.5 with 1 M Trizma base. 
Protein extracts were prepared after 48 h of cultivation. Acetyl-CoA synthetase, carnitine acetyltransferase, 
citrate synthase and alcohol dehydrogenase activity were measured as described in Methods. The values are 
the mean of at least three independent experiments (+/− standard error of the mean (SEM)). cOne unit of 
alcohol dehydrogenase is defined as the amount of enzyme forming 1 µmol of NADH per minute. dOne unit 
of acetyl-CoA synthetase is defined as the amount of enzyme forming 1 µmol of NADH per minute. eOne unit 
of carnitine acetyltransferase is defined as the amount of enzyme that catalyzes the acetylation of 1 µmol of 
reduced coenzyme A (CoASH) per minute. fOne unit of citrate synthase is defined as the amount of enzyme 
forming 1 µmol of reduced coenzyme A (CoASH) per minute. ***(P < 0.001); **(P < 0.01); *(P < 0.05); NS, 
(P ≥ 0.05); aspirin treatment vs no treatment, unpaired two-tailed t-test.
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number of key enzymes required for these acetyl-CoA pathways in MnSOD-deficient cells, but not in wild-type 
cells. Prominent among these impaired enzymes are the ADH2-encoded isoform of alcohol dehydrogenase, 
Adh2, and the yeast acetyl-CoA synthetase (ACS) enzymes (Table 2). As illustrated in Fig. 7, these enzymes 
play crucial successive roles in the synthesis of acetyl-CoA in yeast cells grown in ethanol medium26,33–36. Whilst 
this is the first reported incidence of aspirin-induced inactivation of Adh2 and ACS activity in yeast, aspirin has 
been shown to exert an inhibitory effect on gastric alcohol dehydrogenase activity in humans53,54. Furthermore, 
the aspirin metabolite, salicylate, has been reported to impair mammalian medium-chain acyl-CoA synthetase 
activity in vitro55.
Likewise, in EG110 cells, aspirin impaired the activities of yeast carnitine acetyltransferases and peroxisomal 
citrate synthase (Table 2), which respectively play indispensable roles in the carnitine shuttle and glyoxylate path-
ways to facilitate transport of acetyl-CoA to the mitochondria37,38,43 (Fig. 7). Similar findings in mammalian cell 
models have shown that salicylates interfere with carnitine shuttle transport, by inactivation of carnitine acetyl 
transferases56 and sequestration of both carnitine and reduced coenzyme-A57.
Our results, therefore, indicate that in redox-compromised EG110 yeast cells grown in ethanol medium, 
aspirin heavily interfered with the synthesis of acetyl-CoA and its supply to the mitochondria. This could well 
account for the energy failure and widespread mitochondrial dysfunction previously observed in aspirin-treated 
MnSOD-deficient yeast cells, as indicated by a decreased respiratory rate, disrupted mitochondrial membrane 
potential, and release of cytochrome c20. Interestingly, since acetyl-CoA is essential for the acetylation status 
of chromatin histones58, inhibition of acetyl-CoA synthesis as indicated in this study might partly explain the 
downregulation of our genes of interest in aspirin-treated EG110 yeast cells (Table 1, Fig. 4). In support of this, 
Takahashi and colleagues59 showed that inactivation of ACS enzymes is followed by rapid histone deacetylation 
and significant downregulation of gene expression in yeast. More recent studies have shown that salicylate caused 
profound histone deacetylation in human leukemia, osteosarcoma and colorectal cancer cell lines60–62.
The aspirin-induced disruption of both acetyl-CoA synthesis and transport in EG110 yeast cells, may also 
have occurred as a consequence of dysfunctional mitochondria, already rendered prone to oxidative stress by 
their lack of MnSOD. Past work carried out in our laboratory has consistently shown that aspirin-induced apop-
tosis of MnSOD-deficient yeast cells is preceded by mitochondrial dysfunction-associated events20. Prominent 
among these is the accumulation of mitochondrial superoxide radicals, the attenuation of which (via introduction 
of Escherichia coli iron-superoxide dismutase into the mitochondria of EG110 yeast cells) was a key factor in 
averting aspirin-induced apoptosis21. Moreover, in the present study, the induced overexpression of active Adh2 
(Fig. 6a), which was heavily impaired by aspirin (Table 2) and lies upstream of all other acetyl-CoA synthesis 
and transport pathways in yeast grown on ethanol medium36 (Fig. 7), failed to prevent aspirin-induced cell death 
(Fig. 6b,c). This result might suggest that aspirin-induced impairment of yeast Adh2 (Table 2) is due to underlying 
mitochondrial dysfunction, since activity of this enzyme is regulated by the functional state of mitochondria and 
is positively induced by metabolites involved in the TCA cycle63. In light of all of this, it is strongly implied that 
the mitochondrial milieu plays a critical role in aspirin-mediated EG110 cell death. In fact, it is not surprising 
that perhaps, due to the pleiotropic effects of aspirin, restoring activity of a single enzyme within the acetyl-CoA 
synthesis pathway from ethanol, such as with the overexpression of active Adh2 (Fig. 6a), was not sufficient to 
completely overcome aspirin-induced mitochondrial acetyl-CoA deficiency and cell death.
The suggested influence of aspirin on acetyl-CoA metabolic pathways in our redox-compromised yeast cells 
may provide the key for understanding the chemopreventive, antineoplastic effects of aspirin in early develop-
ing tumour cells, which also suffer increased oxidative stress and altered metabolism17,64–66. The depletion of 
acetyl-CoA by aspirin would very likely exert an apoptotic effect on target cancer cells, since acetyl-CoA plays 
a central role in critical cellular pathways such as energy generation and biosynthesis. For example, acetyl-CoA 
Figure 5. Representative immunoblot using a HA-specific antibody. EG103 is the wild-type strain, whilst 
EG110 is the MnSOD-deficient yeast strain. HA-tagged Adh2 (ADH2-6HA and pGPD-3HA-ADH2) strains were 
cultivated in YPE medium with or without ASA for 48 h and subjected to immunoblot analysis from whole cell 
extracts. The strains either carried the endogenous ADH2 promotor or the constitutive GPD promotor (pGPD) 
as indicated. Full-length blots are presented in Supplementary Fig. S5.
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serves as a critical precursor substrate for the de novo synthesis of fatty acids mediated by cytosolic fatty acid syn-
thase (FASN), known to be a central factor underlying the survival, uncontrolled proliferation and progression 
of numerous types of cancer cells67,68. The importance of acetyl-CoA metabolism in cancer cells is further under-
scored by studies which show that the rate of synthesis of acetyl-CoA, mediated by the mammalian cytosolic 
enzyme acetyl-CoA synthetase (ACSS2), is significantly elevated in several malignant cell lines67,68 in order to 
satisfy their high energy requirements, particularly under conditions of metabolic stress.
The strong reliance of cancer cells on metabolic pathways that supply acetyl-CoA, has recently raised interest 
in the potential use of antineoplastic agents targeting acetyl-CoA. For instance, studies have shown that tar-
geted inhibition of ACSS2-mediated acetyl-CoA synthesis caused growth inhibition of cultured tumor cells and 
significantly reduced the growth and size of tumor xenografts in mice67. Likewise, targeted disruption of key 
carnitine shuttle enzymes mediating transport of acetyl-CoA to the cytosol of lymphoma cancer cells for fatty 
Figure 6. Comparison of (a) alcohol dehydrogenase (Adh2) activity, (b) growth and (c) viability of EG110-
pGPD-ADH2 to those of EG110 yeast cells, grown in ethanol medium (YPE) in the absence and presence of 
15 mM aspirin (ASA). (a) Adh2 activity levels in total cell extracts of redox-compromised (MnSOD-deficient) 
Saccharomyces cerevisiae EG110 cells and recombinant EG110 pGPD-ADH2 cells (EG110 cells where the 
endogenous ADH2 gene promoter has been replaced with the yeast glyceraldehyde phosphate dehydrogenase 
(GPD) gene promoter) grown aerobically for 48 h in YPE medium at 28 °C, 250 rpm, in the absence (represented 
by the white bars) and presence (represented by the grey bars) of 15 mM ASA. Each vertical bar represents the 
mean of at least four experimental determinations of Adh2 activity. Error bars represent the standard error of the 
mean (SEM). NS, not significant (P > 0.05); **, moderately significant (P < 0.01); unpaired two-tailed t-test.  
(b) Growth curves of S. cerevisiae EG110 and EG110 pGPD-ADH2 cells during aerobic cultivation in YPE medium 
in the absence and presence of 15 mM ASA at 28 °C (with constant shaking at 250 rpm). Each point represents the 
average of at least three independent sets of absorbance readings, measured at a wavelength of 600 nm. Error bars 
represent the SEM and appear where sufficiently large. (c) Fold change in viability of EG110 and EG110 pGPD-
ADH2 yeast cells grown in YPE medium in the absence and presence of aspirin, normalized against EG110 yeast 
cells grown in YPE medium, as determined from colony-forming unit (cfu) counts. Each vertical bar represents the 
mean of at least three independent determinations. Error bars represent the SEM. NS, not significant (P > 0.05); 
**, moderately significant (P < 0.01), (One-way ANOVA with Bonferroni post-hoc tests).
1 1Scientific RepoRts |          (2019) 9:6152  | https://doi.org/10.1038/s41598-019-39489-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
acid synthesis, was shown to cause a cytotoxic depletion of acetyl-CoA and growth inhibition in these cells69. In 
addition, cross-talk between acetylation and histone modifications strongly implicate acetyl-CoA in the regula-
tion of chromatin acetylation and gene expression70,71. Hence, the strong association between aspirin and impair-
ment of acetyl-CoA metabolism, highlighted in this study, merits further investigation in the context of aspirin’s 
anti-cancer properties.
References
 1. Rothwell, P. M. et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from 
randomised trials. Lancet 377, 31–41, https://doi.org/10.1016/S0140-6736(10)62110-1 (2011).
 2. Alfonso, L., Ai, G., Spitale, R. C. & Bhat, G. J. Molecular targets of aspirin and cancer prevention. Br. J. Cancer. 111, 61–67, https://
doi.org/10.1038/bjc.2014.271 (2014).
 3. Cuzick, J. et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. 26, 47–57, 
https://doi.org/10.1093/annonc/mdu225 (2015).
 4. Chan, A. T. et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev. Res. (Phila). 5, 164–178, https://
doi.org/10.1158/1940-6207.CAPR-11-0391 (2012).
 5. Gurpinar, E., Grizzle, W. E. & Piazza, G. A. COX-independent mechanisms of cancer chemoprevention by anti-inflammatory drugs. 
Front Oncol. 3, 181, https://doi.org/10.3389/fonc.2013.00181 (2013).
 6. Madeo, F., Fröhlich, E. & Fröhlich, K.-U. A yeast mutant showing diagnostic markers of early and late apoptosis. J. Cell Biol. 139, 
729–734 (1997).
 7. Carmona-Gutierrez, D. et al. Apoptosis in yeast: triggers, pathways, subroutines. Cell Death Differ. 17, 763–773, https://doi.
org/10.1038/cdd.2009.219 (2010).
 8. Farrugia, G. & Balzan, R. Oxidative stress and programmed cell death in yeast. Front. Oncol. 64, 1–21, https://doi.org/10.3389/
fonc.2012.00064 (2012).
 9. Carmona-Gutierrez, D. et al. Guidelines and recommendations on yeast cell death nomenclature. Microbial Cell 5, 4–31, https://doi.
org/10.15698/mic2018.01.607 (2018).
 10. Eisenberg, T., Büttner, S., Kroemer, G. & Madeo, F. The mitochondrial pathway in yeast apoptosis. Apoptosis 12, 1011–23, https://
doi.org/10.1007/s10495-007-0758-0 (2007).
 11. Galluzzi, L., Kepp, O. & Kroemer, G. Mitochondrial regulation of cell death: a phylogenetically conserved control. Microb. Cell 3, 
101–108, https://doi.org/10.15698/mic2016.03.483 (2016).
 12. Knorre, D. A., Sokolov, S. S., Zyrina, A. N. & Severin, F. F. How do yeast sense mitochondrial dysfunction? Microb. Cell 3, 532–539, 
https://doi.org/10.15698/mic2016.11.537 (2016).
 13. Xu, Y. et al. Manganese superoxide dismutase deficiency triggers mitochondrial uncoupling and the Warburg effect. Oncogene 34, 
4229–4237, https://doi.org/10.1038/onc.2014.355 (2015).
 14. Oberley, L. W. & Buettner, G. R. Role of superoxide dismutase in cancer: a review. Cancer Res. 39, 1141–1149 (1979).
 15. Dhar, S. K., Tangpong, J., Chaiswing, L., Oberley, T. D. & St. Clair, D. K. Manganese superoxide dismutase is a p53-regulated gene that 
switches cancers between early and advanced stages. Cancer Res. 71, 6684–6695, https://doi.org/10.1158/0008-5472.CAN-11-1233 
(2011).
 16. Holley, A. K., Dhar, S. K. & St. Clair, D. K. Curbing cancer’s sweet tooth: is there a role for MnSOD in regulation of the Warburg 
effect? Mitochondrion 13, 170–188, https://doi.org/10.1016/j.mito.2012.07.104 (2013).
 17. Qin, Y., Dai, W., Wang, Y., Gong, X. G. & Lu, M. Fe-SOD cooperates with Nutlin3 to selectively inhibit cancer cells in vitro and in 
vivo. Biochem. Biophys. Res. Commun. 431, 169–175, https://doi.org/10.1016/j.bbrc.2013.01.001 (2013).
 18. Balzan, R. et al. Aspirin commits yeast cells to apoptosis depending on carbon source. Microbiology 150, 109–115, https://doi.
org/10.1099/mic.0.26578-0 (2004).
 19. Sapienza, K. & Balzan, R. Metabolic aspects of aspirin-induced apoptosis in yeast. FEMS Yeast Res. 5, 1207–1213, https://doi.
org/10.1016/j.femsyr.2005.05.001 (2005).
Figure 7. Aspirin-induced impairment of acetyl-CoA metabolism. Aspirin (ASA) downregulates genes 
involved in the synthesis (ADH2 and ACS1) and transport (such as CAT2, YAT2 and CIT2) of acetyl-CoA to 
the mitochondria and decreases the activity of their gene products in the MnSOD-deficient Saccharomyces 
cerevisiae EG110 cells (downregulated pathways shown in dotted red lines). ATP, adenosine triphosphate; 
CoA, coenzyme A; CoASH, reduced coenzyme A; FADH2, reduced flavin adenine dinucleotide; GC, glyoxylate 
cycle; GTP, guanosine triphosphate; MnSOD, manganese superoxide dismutase; NADH, reduced nicotinamide 
adenine dinucleotide; TCA, tricarboxylic acid cycle.
1 2Scientific RepoRts |          (2019) 9:6152  | https://doi.org/10.1038/s41598-019-39489-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
 20. Sapienza, K., Bannister, W. & Balzan, R. Mitochondrial involvement in aspirin- induced apoptosis in yeast. Microbiology 154, 
2740–2747, https://doi.org/10.1099/mic.0.2008/017228-0 (2008).
 21. Farrugia, G., Bannister, W. H., Vassallo, N. & Balzan, R. Aspirin-induced apoptosis of yeast cells is associated with mitochondrial 
superoxide radical accumulation and NAD(P)H oxidation. FEMS Yeast Res. 13, 755–768, https://doi.org/10.1111/1567-1364.12075 
(2013).
 22. Janke, C. et al. A versatile toolbox for PCR-based tagging of yeast genes: new fluorescent proteins, more markers and promoter 
substitution cassettes. Yeast 21, 947–962, https://doi.org/10.1002/yea.1142 (2004).
 23. Irizarry, R. A. et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, e15, https://doi.org/10.1093/nar/
gng015 (2003).
 24. Metsalu, T. & Vilo, J. ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and 
heatmap. Nucleic Acids Research 43, 566–570, https://doi.org/10.1093/nar/gkv468 (2015).
 25. Vallee, B. L. & Hoch, F. L. Yeast Alcohol Dehydrogenase, A Zinc Metalloenzyme. J. Am. Chem. Soc. 77, 821–82 (1955).
 26. van den Berg, M. A. et al. The two acetyl-coenzyme A synthetases of Saccharomyces cerevisiae differ with respect to kinetic properties 
and transcriptional regulation. J. Biol. Chem. 271, 28953–28959, https://doi.org/10.1074/jbc.271.46.28953 (1996).
 27. Chase, J. F. A. Carnitine acetyltransferase from pigeon breast muscle. Methods Enzymol. 13, 387–393, https://doi.org/10.1016/0076-
6879(69)13066-9 (1969).
 28. Srere, P. A. Citrate Synthase: [EC 4.1.3.7. Citrate oxaloacetate-lyase (CoA-acetylating)]. Methods Enzymol 13, 3–11, https://doi.
org/10.1016/0076-6879(69)13005-0 (1969).
 29. Glick, B. S. & Pon, L. A. Isolation of highly purified mitochondria from Saccharomyces cerevisiae. Methods Enzymol. 260, 213–233, 
https://doi.org/10.1016/0076-6879(95)60139-2 (1995).
 30. Riezman, H. et al. Import of proteins into mitochondria: a 70 kilodalton outer membrane protein with a large carboxy-terminal 
deletion is still transported to the outer membrane. EMBO J. 2, 2161–2168 (1983).
 31. Piqué, M. et al. Aspirin induces apoptosis through mitochondrial cytochrome c release. FEBS Lett. 480, 193–196, https://doi.
org/10.1016/S0014-5793(00)01922-0 (2000).
 32. Raza, H., John, A. & Benedict, S. Acetylsalicylic acid-induced oxidative stress, cell cycle arrest, apoptosis and mitochondrial 
dysfunction in human hepatoma HepG2 cells. Eur. J. Pharmacol. 668, 15–24, https://doi.org/10.1016/j.ejphar.2011.06.016 (2011).
 33. Chen, Y., Siewers, V. & Nielsen, J. Profiling of cytosolic and peroxisomal acetyl- CoA metabolism in Saccharomyces cerevisiae. PLoS 
One 7, e42475, https://doi.org/10.1371/journal.pone.0042475 (2012).
 34. Galdieri, L., Zhang, T., Rogerson, D., Lleshi, R. & Vancura, A. Protein acetylation and acetyl coenzyme a metabolism in budding 
yeast. Eukaryotic cell 13, 1472–1483, https://doi.org/10.1128/EC.00189-14 (2014).
 35. Ciriacy, M. Genetics of alcohol dehydrogenase in Saccharomyces cerevisiae. II. Two loci controlling synthesis of the glucose-
repressible ADH II. Mol. Gen. Genet. 138, 157–164 (1975).
 36. Turcotte, B., Liang, X. B., Robert, F. & Soontorngun, N. Transcriptional regulation of nonfermentable carbon utilization in budding 
yeast. FEMS Yeast Res. 10, 2–13, https://doi.org/10.1111/j.1567-1364.2009.00555.x (2009).
 37. Schmalix, W. & Bandlow, W. The ethanol-inducible YAT1 gene from yeast encodes a presumptive mitochondrial outer carnitine 
acetyltransferase. J. Biol. Chem 268, 27428–27439 (1993).
 38. van Roermund, C. W., Elgersma, Y., Singh, N., Wanders, R. J. & Tabak, H. F. The membrane of peroxisomes in Saccharomyces 
cerevisiae is impermeable to NAD(H) and acetyl-CoA under in vivo conditions. EMBO J. 14, 3480–3486 (1995).
 39. Palmieri, L. et al. Identification of the yeast ACR1 gene product as a succinate–fumarate transporter essential for growth on ethanol 
or acetate. FEBS Lett. 417, 114–118, https://doi.org/10.1016/S0014-5793(97)01269-6 (1997).
 40. Lewin, A. S., Hines, V. & Small, G. M. Citrate synthase encoded by the CIT2 gene of Saccharomyces cerevisiae is peroxisomal. Mol. 
Cell. Biol. 10, 1399–1405 (1990).
 41. Elgersma, Y., van Roermund, C. W., Wanders, R. J. & Tabak, H. F. Peroxisomal and mitochondrial carnitine acetyltransferases of 
Saccharomyces cerevisiae are encoded by a single gene. EMBO J. 14, 3472–3479 (1995).
 42. Palmieri, L. et al. Identification of the mitochondrial carnitine carrier in Saccharomyces cerevisiae. FEBS Lett. 462, 472–476, https://
doi.org/10.1016/S0014-5793(99)01555-0 (1999).
 43. Swiegers, J. H., Dippenaar, N., Pretorius, I. S. & Bauer, F. F. Carnitine-dependent metabolic activities in Saccharomyces cerevisiae: 
three carnitine acetyltransferases are essential in a carnitine-dependent strain. Yeast 18, 585–595 (2001).
 44. van Roermund, C. W., Hettema, E. H., van den Berg, M., Tabak, H. F. & Wanders, R. J. Molecular characterization of carnitine-
dependent transport of acetyl- CoA from peroxisomes to mitochondria in Saccharomyces cerevisiae and identification of a plasma 
membrane carnitine transporter, Agp2p. EMBO J. 18, 5843–5852, https://doi.org/10.1093/emboj/18.21.5843 (1999).
 45. Dibra, H. K., Brown, J. E., Hooley, P. & Nicholl, I. D. Aspirin and alterations in DNA repair proteins in the SW480 colorectal cancer 
cell line. Oncol. Rep. 24, 37–46, https://doi.org/10.3892/or_00000826 (2010).
 46. Satyanarayana, T., Mandel, A. D. & Klein, H. P. Evidence for two immunologically distinct acetyl-CO-enzyme a synthetases in yeast. 
Biochim. et Biophys. Acta (BBA)-Enzymol. 341, 396–401, https://doi.org/10.1016/0005-2744(74)90232-0 (1974).
 47. van den Berg, M. A. & Steensma, H. Y. ACS2, a Saccharomyces cerevisiae gene encoding acetyl-coenzyme A synthetase, essential for 
growth on glucose. Eur. J. Biochem. 231, 704–713 (1995).
 48. Franken, J., Kroppenstedt, S., Swiegers, J. H. & Bauer, F. F. Carnitine and carnitine acetyltransferases in the yeast Saccharomyces 
cerevisiae: a role for carnitine in stress protection. Curr Genet. 53, 347–360, https://doi.org/10.1007/s00294-008-0191-0 (2008).
 49. Suissa, M., Suda, K. & Schatz, G. Isolation of the nuclear yeast genes for citrate synthase and fifteen other mitochondrial proteins by 
a new screening method. EMBO J. 3, 1773–1781 (1984).
 50. Jia, Y. K., Bécam, A. M. & Herbert, C. J. The CIT3 gene of Saccharomyces cerevisiae encodes a second mitochondrial isoform of citrate 
synthase. Mol. Microbiol. 24, 53–59, https://doi.org/10.1046/j.1365-2958.1997.3011669.x (1997).
 51. Wills, C. Production of yeast alcohol dehydrogenase isoenzymes by selection. Nature 261, 26–29, https://doi.org/10.1038/261026a0 
(1976).
 52. Russell, D. W., Smith, M., Williamson, V. M. & Young, E. T. Nucleotide sequence of the yeast alcohol dehydrogenase II gene. J. Biol. 
Chem. 258, 2674–2682 (1983).
 53. Gentry, R. T. et al. Mechanism of the aspirin-induced rise in blood alcohol levels. Life Sci. 65, 2505–2512 (1999).
 54. Lee, S. L. et al. Inhibition of human alcohol and aldehyde dehydrogenases by aspirin and salicylate: assessment of the effects on first-
pass metabolism of ethanol. Biochem. Pharmacol. 95, 71–79, https://doi.org/10.1016/j.bcp.2015.03.003 (2015).
 55. Kasuya, F., Hiasa, M., Kawai, Y., Igarashi, K. & Fukui, M. Inhibitory effect of quinolone antimicrobial and nonsteroidal anti-
inflammatory drugs on a medium chain acyl- CoA synthetase. Biochem. Pharmacol. 62, 363–367 (2001).
 56. Vessey, D. A., Chen, W. & Ramsay, R. R. Effect of carboxylic acid xenobiotics and their metabolites on the activity of carnitine 
acyltransferases. Biochem. J. 279, 895–897 (1991).
 57. Deschamps, D. et al. Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids. Possible role in the 
development of Reye’s syndrome. J. Pharmacol. Exp. Ther. 259, 894–904 (1991).
 58. Lee, T. I. et al. Redundant roles for the TFIID and SAGA complexes in global transcription. Nature 6787, 701–704, https://doi.
org/10.1038/35015104 (2000).
 59. Takahashi, H., MacCaffery, J. M., Irizarry, R. A. & Boeke, J. D. Nucleocytosolic acetyl-coenzyme A synthetase is required for histone 
acetylation and global transcription. Mol. Cell. 23, 207–217, https://doi.org/10.1016/j.molcel.2006.05.040 (2006).
13Scientific RepoRts |          (2019) 9:6152  | https://doi.org/10.1038/s41598-019-39489-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
 60. Shirakawa, K. et al. Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity. Elife, 5 https://doi.
org/10.7554/eLife.11156 (2016).
 61. Fernandez, H. R. & Lindén, S. K. The aspirin metabolite salicylate inhibits lysine acetyltransferases and MUC1 induced epithelial to 
mesenchymal transition. Scientific reports 7, 5626, https://doi.org/10.1038/s41598-017-06149-4 (2017).
 62. Pietrocola, F. et al. Aspirin Recapitulates Features of Caloric Restriction. Cell Reports 22, 2395–2407, https://doi.org/10.1016/j.
celrep.2018.02.024 (2018).
 63. Wills, C. & Martin, T. Extracellular conditions affecting the induction of yeast alcohol dehydrogenase II. Biochim. Biophys. Acta 782, 
274–284, https://doi.org/10.1016/0167-4781(84)90063-0 (1984).
 64. Warburg, O. On the origin of cancer cells. Science 123, 309–314 (1956).
 65. El Sayed, S. M. et al. Warburg effect increases steady-state ROS condition in cancer cells through decreasing their antioxidant 
capacities (anticancer effects of 3-bromopyruvate through antagonizing Warburg effect). Med. Hypotheses 81, 866–870, https://doi.
org/10.1016/j.mehy.2013.08.024 (2013).
 66. Konzack, A. & Kietzmann, T. Manganese superoxide dismutase in carcinogenesis: friend or foe? Biochem. Soc. Trans. 42, 1012–1016, 
https://doi.org/10.1042/BST20140076 (2014).
 67. Schug, Z. T. et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. 
Cancer Cell 27, 57–71, https://doi.org/10.1016/j.ccell.2014.12.002 (2015).
 68. Yoshii, Y., Furukawa, T., Saga, T. & Fujibayashi, Y. Acetate/acetyl-CoA metabolism associated with cancer fatty acid synthesis: 
overview and application. Cancer Lett. 356, 211–216, https://doi.org/10.1016/j.canlet.2014.02.019 (2015).
 69. Pacilli, A. et al. Carnitine- acyltransferase system inhibition, cancer cell death, and prevention of myc-induced lymphomagenesis. J. 
Natl. Cancer Inst. 105, 489–498, https://doi.org/10.1093/jnci/djt030 (2013).
 70. Marmorstein, R. & Roth, S. Y. Histone acetyltransferases: function, structure, and catalysis. Curr. Opin. Genet. Dev. 11, 155–161, 
https://doi.org/10.1016/S0959-437X(00)00173-8 (2001).
 71. Marmorstein, R. Structure and function of histone acetyltransferases. Cell. Mol. Life Sci. 58, 693–703, https://doi.org/10.1007/
PL00000893 (2001).
Acknowledgements
We are grateful to Dr. Nikolai P. Pace for his technical advice on the extraction of RNA and use of the Bioanalyzer. 
This work was financed by the Malta Council for Science and Technology through the R&I Technology 
Development Programme (Project R & I-2015-001). We also would like to thank the University of Malta. F.M. is 
grateful to the Austrian Science Fund FWF (Austria) for grants P23490-B20, P29262, P24381, P29203 P27893, 
I1000, and “SFB Lipotox” (F3012), as well as to Bundesministerium für Wissenschaft, Forschung und Wirtschaft 
and the Karl-Franzens University for grant “Unkonventionelle Forschung” and grant DKplus Metabolic and 
Cardiovascular Diseases (W1226). FM acknowledges support from NAWI Graz and the BioTechMed-Graz 
flagship project “EPIAge”.
Author Contributions
G.F. carried out most of the laboratory work, produced the initial results dataset and drafted most of the 
manuscript. M.A., C.S. and A.S.G. contributed to the laboratory work and to the drafting of the manuscript. 
T.E., N.V., G.G. and F.M. contributed to the design of the experiments and in editing the manuscript. J.P. and V.B. 
helped with the microarray analysis and the statistics involved in interpretation of results. J.B. contributed to the 
statistical studies involved in microarray analysis. R.B. conceived the project, designed most of the experiments 
and contributed in writing the manuscript. All authors read the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-39489-4.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
